Request Demo
Blackstone injects $140M cash into Sutro Biopharma for Vaxcyte royalties
VaccineClinical ResultPhase 2License out/inPhase 1
Vaxcyte is a next-gen vaccine company formed around Sutro Biopharma's tech.
Vaxcyter Blackstone Life Sciences is paying Sutro BiSutro Biopharmallion cash and throwing in another potential $250 million in biobucks in exchange for royalties on possible future sales of Vaxcyte’s products.
Vaxcyte iBlackstone Life Sciencespany formedSutro Biopharma platform technology. Now, the company is the center of a royalty financing pact between Blackstone and Sutro, which holds a 4% royaVaxcytethe potential future sales of Vaxcyte’s products.
Vaxcyte’s aiming to pry open Pfizer’s tight grip on Sutroneumococcal market with lead candidate VAX-24, a phase 3-ready pneumococcal conjugate vacciBlackstoneroundSutroo’s cell-free protein synthesis tech.Vaxcyte
Vaxcytel, Vaxcyte shared phasPfizerta that found its asset showed non-inferiority against 90% ofVAX-24erotypes covered by Pfizer’s Prevnar 20 among adults 65 and olSutrond was superior against the four serotypes unique to Vaxcyte’s candidate. Vaxcyte said its vaccine has a similar tolerability profile to Prevnar 20 across all patients 18 and older, with most local and system reactions classed as mild to moderate.
Vaxcyte isVaxcytea few years away from a possible market entry for VAX-24 but said it will speak to regulators about phasePfizerns and expects a readout in 2025. It’s a similar timeline for the vaccine in infants, an indicVaxcytehere Vaxcyte wVaxcytee to battle against both Merck and Pfizer if it gains approval.
Vaxcyteshly inked deal will allow Sutro to advance its own pipelineVAX-24ifically an antibody-drug conjugate called luveltamab tazevibulin, Sutro CEO Bill Newell said in a June 26 release. The company recently launched a late-stage stVaxcyteluating the asset in patients withMerckinum-Pfizerant ovarian cancer. Sutro will also focus on its other wholly owned ADC, the CD74-targeting STRO-001 currently being evaluated in clinical studies for B-cell malignancies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.